Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its analysis of proprietary late clinical stage NBN-Pac formulations, namely IG-001 (Cynviloq) and IG-004 (a D-a-tocopheryl polyethylene glycol succinate (TPGS)-based paclitaxel formulation) at the annual Nanomedicine 2013 meeting in Barcelona, Spain (April 11th - 12th).

8 Apr 2013

One cohort of Phase 2 NSCLC study fails to meet primary endpoint, Merrimack says

Merrimack Pharmaceuticals, Inc. today announced that one cohort of a Phase 2 non-small cell lung cancer study did not meet its primary endpoint. The cohort evaluated MM-121 in combination with erlotinib to treat patients with NSCLC whose disease progressed on an anti-EGFR tyrosine kinase inhibitor (EGFR-TKI).

5 Apr 2013

Researchers identify vulnerability of lung-cancer cells that can be exploited for new therapies

Physician-researchers at UT Southwestern Medical Center have identified a vulnerability of certain lung-cancer cells - a specific genetic weakness that can be exploited for new therapies.

4 Apr 2013

PARP inhibitors can be novel treatment strategy for cisplatin-resistant cancer

Poly (ADP-ribose) polymerase inhibitors may be a novel treatment strategy for patients with cancer that has become resistant to the commonly used chemotherapy drug cisplatin, according to data from a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.

3 Apr 2013

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

NewLink Genetics Corporation, a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a double-blind, randomized, placebo-controlled Phase 2 clinical study of its first IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, indoximod, in patients with metastatic breast cancer.

2 Apr 2013

Phase II study shows effectiveness of Axelar's AXL-003 in treating patients with NSCLC

Axelar AB, part of the Karolinska Development AB portfolio, announced today that preliminary interim results of its Phase II study AXL-003, indicates that AXL1717 is effective in treating patients with non-small cell lung cancer.

2 Apr 2013

Phase 2 study of REOLYSIN meets primary endpoint in patients with squamous cell lung cancer

Oncolytics Biotech Inc. today announced that it has met the primary overall statistical endpoint in its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel in patients with metastatic stage IIIB, or stage IV, or recurrent SCCLC who are chemotherapy naïve for their metastatic or recurrent cancer (REO 021).

28 Mar 2013

Neurological researchers study promising new treatment for deadly brain tumors

A promising new treatment for deadly brain tumors taken orally with minimal side effects is being studied by neurological researchers at Rush University Medical Center, Chicago.

28 Mar 2013

CureVac begins CV9104 Phase 2b clinical trial in patients with castration-resistant prostate cancer

CureVac GmbH, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA, today announced that it has initiated a double-blind, randomized Phase 2b clinical trial of its RNActive cancer vaccine, CV9104, for the treatment of patients with castration-resistant prostate cancer.

28 Mar 2013

Researchers identify patterns of mutations in early stage node negative lung adenocarcinoma

Molecular driven therapeutic targets have resulted in a paradigm shift in the treatment of advanced lung adenocarcinoma. However, in early non-small cell lung cancer, surgical resection remains the treatment of choice with adjuvant chemotherapy.

25 Mar 2013

Results from GTx's Phase 2 clinical trial of enobosarm published online

GTx, Inc. today announced that the journal, The Lancet Oncology, has published online ahead of its April print edition the results from GTx's randomized, double-blind, placebo-controlled Phase 2 clinical trial of enobosarm to assess its effects on muscle wasting and physical function in patients with cancer.

15 Mar 2013

Global Blood Therapeutics, Array BioPharma partner for drug discovery research

Array BioPharma Inc. and Global Blood Therapeutics today announced a multi-target drug discovery collaboration agreement to identify small molecule lead compounds targeting chronic blood-based diseases.

6 Mar 2013

Better representation of elderly patients in phase III trials can improve evidence-based treatment

The median age of patients diagnosed with advanced non-small-cell lung cancer (NSCLC) has steadily increased over the recent years and is presently 70 years. Despite this, the elderly are significantly underrepresented in clinical trials.

25 Feb 2013

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

ADCs are used for a new type of targeted therapy that consists of a specific anti-cancer antibody or antibody fragment linked to a potent anti-cancer therapeutic.

20 Feb 2013

IKBKE gene plays a key role in tobacco-induced lung cancer

Researchers at Moffitt Cancer Center have found a potential targeted therapy for patients with tobacco-associated non-small cell lung cancer. It is based on the newly identified oncogene IKBKE, which helps regulate immune response.

16 Feb 2013

SUVmax may help indicate progression-free survival in stage I NSCLC patients treated with SBRT

SUVmax (Maximum Standardized Uptake Value) may be a significant and clinically independent marker to indicate progression-free survival in stage I non-small cell lung cancer (NSCLC) patients treated with stereotactic body radiation therapy (SBRT), according to research being presented at the 2013 Cancer Imaging and Radiation Therapy Symposium.

10 Feb 2013

Positive data from Oncolytics' REOLYSIN Phase 2 combination trial on SCCLC

Oncolytics Biotech Inc. today announced results examining percent overall tumour shrinkage data from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel (REO 021).

9 Feb 2013

Start palliative care early for optimum results

Palliative care provided early in the ambulatory care setting varies with the trajectory of patients’ disease and is complementary to medical management, show study results.

6 Feb 2013

RRM1 gene may better predict survival for pancreatic adenocarcinoma

Moffitt Cancer Center researchers have identified a gene that may better predict survival for pancreatic adenocarcinoma, the fourth leading cause of cancer deaths in the United States.

6 Feb 2013

Cerulean initiates CRLX101 Phase 2 study in extensive-stage small cell lung cancer

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a randomized Phase 2 study of its lead candidate, CRLX101, in patients with extensive-stage small cell lung cancer (SCLC) sensitive to first-line platinum-based chemotherapy.

31 Jan 2013

Small Cell Lung Cancer News and Research

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

One cohort of Phase 2 NSCLC study fails to meet primary endpoint, Merrimack says

Researchers identify vulnerability of lung-cancer cells that can be exploited for new therapies

PARP inhibitors can be novel treatment strategy for cisplatin-resistant cancer

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

Phase II study shows effectiveness of Axelar's AXL-003 in treating patients with NSCLC

Phase 2 study of REOLYSIN meets primary endpoint in patients with squamous cell lung cancer

Neurological researchers study promising new treatment for deadly brain tumors

CureVac begins CV9104 Phase 2b clinical trial in patients with castration-resistant prostate cancer

Researchers identify patterns of mutations in early stage node negative lung adenocarcinoma

Results from GTx's Phase 2 clinical trial of enobosarm published online

Global Blood Therapeutics, Array BioPharma partner for drug discovery research

Better representation of elderly patients in phase III trials can improve evidence-based treatment

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

IKBKE gene plays a key role in tobacco-induced lung cancer

SUVmax may help indicate progression-free survival in stage I NSCLC patients treated with SBRT

Positive data from Oncolytics' REOLYSIN Phase 2 combination trial on SCCLC

Start palliative care early for optimum results

RRM1 gene may better predict survival for pancreatic adenocarcinoma

Cerulean initiates CRLX101 Phase 2 study in extensive-stage small cell lung cancer

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News